Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

DISEASE CHARACTERISTICS:

* Histologically confirmed hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC)

  * Peripheral, cholangiolar, or cholangiocellular types
  * Mixed HCC/ICC disease allowed
  * Unresectable disease
  * Less than 70% liver involvement
* Radiographically bidimensionally measurable disease, defined as lesion ≥ 2 cm in the greatest diameter
* May have failed prior systemic chemotherapy or ablative therapy
* No radiographic evidence of esophageal varices
* No history of variceal hemorrhage
* No occlusion of the main portal vein or the right and left portal branches
* No clinical ascites
* Patients ineligible for first-line MSKCC protocols for HCC are eligible for this study provided there is no clinical or radiographic evidence of extrahepatic disease
* No metastatic disease, including CNS metastases

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 12 weeks
* Karnofsky performance status 60-100%
* Considered a candidate for general anesthesia and hepatic artery pump placement
* Platelet count \> 100,000/mm³
* Albumin \> 2.5 g/dL
* Bilirubin \< 1.8 mg/dL
* WBC \> 3,500/mm³
* PTT \< 1.5 times upper limit of normal
* INR \< 1.5 OR in-range INR (usually 2.0-3.0) for patients on a stable dose of therapeutic warfarin
* Urine protein \< 1+ by dipstick or urine analysis OR urine protein:creatinine ratio \< 1.0

  * If proteinuria ≥ 2+ at baseline, patient must have \< 1 g protein/24-hour collection
* No concurrent disease or illness that would preclude study participation, including any of the following:

  * Hepatic encephalopathy
  * Sclerosing cholangitis
  * Gilbert's disease
  * Active infection
* No known CNS disease
* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
* No psychiatric illness or social situation that would preclude study compliance
* No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
* No serious or nonhealing active wound, ulcer, or bone fracture
* No bleeding diathesis or coagulopathy
* No clinically significant cardiovascular disease, including any of the following:

  * Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 100 mm Hg on antihypertensive medications
  * New York Heart Association class II-IV congestive heart failure
  * Vascular disease (e.g., aortic aneurysm, aortic dissection)
  * Myocardial infarction within the past 6 months
  * Symptomatic peripheral vascular disease
  * Unstable angina within the past 6 months
  * History of hypertensive crisis
  * Transient ischemic attack
  * Stroke
* No other concurrent malignancy except localized basal cell or squamous cell skin cancer
* Chronic hepatitis and/or cirrhosis allowed provided it is Child-Pugh class A disease
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* More than 4 weeks since prior and no other concurrent experimental therapy except on a Genentech-sponsored bevacizumab cancer study
* More than 4 weeks since prior major surgical procedure or open biopsy
* More than 1 week since prior minor surgical procedure (e.g., core biopsy), excluding placement of a vascular access device
* No prior external-beam radiation therapy to the liver
* No prior floxuridine
* No chronic daily treatment with nonsteroidal anti-inflammatory medications known to inhibit platelet function
* No chronic daily treatment with aspirin (\> 325 mg/day)
* No concurrent or recent use of a thrombolytic agent
* No concurrent major surgery